×

Relypsa Announces Proposed Public Offering of Common Stock

REDWOOD CITY, Calif., Feb. 24, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that it has commenced an underwritten public offering of up to $130,000,000 of shares of its common stock. All of the shares of the common stock to be sold in the offering will be offered by Relypsa. In addition, Relypsa expects to grant the underwriters a 30 day option to purchase up to an additional $19,500,000 of shares of common stock at the public offering price, less the underwriting discount. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

BofA Merrill Lynch and Cowen and Company are acting as joint book-running managers for the offering. Oppenheimer & Co., Stifel, Nicolaus & Company and Wedbush PacGrow Life Sciences are acting as co-managers for the offering.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission and became effective on December 15, 2014. This offering is being made solely by means of a prospectus. Copies of the preliminary prospectus related to the offering may be obtained from BofA Merrill Lynch, 222 Broadway, New York, New York 10038, Attn: Prospectus Department, or email dg.prospectus_requests@baml.com; or Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, Telephone: 631-274-2806, Fax: 631-254-7140.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Relypsa, Inc.

Relypsa, Inc. is a biopharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases. A New Drug Application for Patiromer for Oral Suspension, Relypsa's lead product candidate for the treatment of hyperkalemia, was accepted by the U.S. Food and Drug Administration and is currently under review.

Forward Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Relypsa, they are forward-looking statements reflecting the current beliefs and expectations of management, including statements regarding the completion, timing, size and use of proceeds of the proposed public offering and possible U.S. regulatory approval and commercial launch of Patiromer FOS. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, market conditions and the satisfaction of closing conditions related to the proposed public offering, and the regulatory approval process. Relypsa undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see Relypsa's current and future reports filed with the U.S. Securities and Exchange Commission, or SEC, including its Annual Report on Form 10-K for the year ended December 31, 2013 and its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2014, as well as the preliminary prospectus for the proposed public offering included as part of the Registration Statement on Form 424(b)(5) related to such offering to be filed with the Securities and Exchange Commission.

CONTACT: Alex Dobbin Associate Director, Investor Relations and Corporate Affairs 650.421.9687 IR@relypsa.com

Source:Relypsa, Inc.